VivoSim Labs Inc
VIVS
Company Profile
Business description
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Contact
11555 Sorrento Valley road
Suite 100
San DiegoCA92121
USAT: +1 858 224-1000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
14
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,203.90 | 28.80 | 0.35% |
| CAC 40 | 7,573.76 | 37.50 | 0.50% |
| DAX 40 | 22,271.67 | 29.22 | 0.13% |
| Dow JONES (US) | 40,002.16 | 111.34 | -0.28% |
| FTSE 100 | 8,417.34 | 2.09 | 0.02% |
| HKSE | 21,971.96 | 8.78 | -0.04% |
| NASDAQ | 17,173.86 | 209.08 | -1.20% |
| Nikkei 225 | 35,839.99 | 134.25 | 0.38% |
| NZX 50 Index | 12,098.89 | 81.05 | 0.67% |
| S&P 500 | 5,484.23 | 40.98 | -0.74% |
| S&P/ASX 200 | 7,997.10 | 28.90 | 0.36% |
| SSE Composite Index | 3,288.41 | 6.65 | -0.20% |